Patents Assigned to GlaxoSmithKline Biological S.A.
  • Method for determining a concentration of a polysorbate species in a mixture
    Patent number: 9134228
    Abstract: The present invention relates to a method of measuring polysorbates, such as polysorbate 80, using Attenuated Total Reflectance-Fourier Transform Infrared spectroscopy (ATR-FTIR).
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: September 15, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Benedicte Gbaguidi, Olivier C Germay, Sonia Lardau
  • Pneumococcal polysaccharide conjugate vaccine
    Patent number: 9107872
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: August 18, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • USE OF ALPHA-TOXIN FOR TREATING AND PREVENTING STAPHYLOCOCCUS INFECTIONS
    Publication number: 20150165015
    Abstract: Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines may comprise one or more other bacterial antigens. Antibody compositions comprising antibodies to alpha-toxin and optionally one or more other bacterial antigens also are provided, and are useful for treating and preventing infections.
    Type: Application
    Filed: October 1, 2012
    Publication date: June 18, 2015
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: GlaxoSmithKline Biologicals S.A.
  • Method for preventing or treating infection
    Patent number: 9056913
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: June 16, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Rhea Coler, Yves Lobet, Steven Reed
  • Lipidated oxoadenine derivatives
    Patent number: 9044481
    Abstract: Provided are novel lipidated oxoadenines which are useful as immunostimulators and adjuvants and are shown to be inducers of interferon-a and other immunostimulatory cytokines.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: June 2, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: David Johnson
  • Vaccine protection assay
    Patent number: 9023606
    Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: May 5, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
  • MAGE antigen binding proteins
    Patent number: 8987423
    Abstract: Antigen binding proteins, such as antibodies, which bind to human MAGE-A3, polynucleotides encoding such antigen binding proteins, and uses and manufacture thereof.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: March 24, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Alain Bergeron, Normand Blais, Remi M. Palmantier, Anthony Pilorget, Yves Fradet
  • Inactivated polio vaccines
    Patent number: 8956625
    Abstract: The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus are provided.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 17, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Herve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
  • Vaccine
    Patent number: 8945582
    Abstract: The standard dose of polio vaccines contains 40 D-antigen units of inactivated poliovirus type 1 (Mahoney), 8 D-antigen units of inactivated poliovirus type 2 (MEF-1), and 32 D-antigens units of inactivated poliovirus type 3 (Saukett). The present invention teaches that reduced doses of inactivated poliovirus can maintain adequate or improved level of protection against polio.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 3, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Herve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
  • Fusion proteins and combination vaccines comprising Protein E and Pilin A
    Patent number: 8945577
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: February 3, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • Lipidated imidazoquinoline derivatives
    Patent number: 8946421
    Abstract: The compounds of the subject invention are adjuvant molecules that comprise an imidazoquinoline molecule covalently linked to a phospho- or phosphonolipid group. The compounds of the invention have been shown to be inducers of interferon-a, IL-12 and other immunostimulatory cytokines and possess an improved activity profile in comparison to known cytokine inducers when used as adjuvants for vaccine antigens.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 3, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: David A. Johnson
  • Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the MAGE-A3-marker
    Patent number: 8936919
    Abstract: The present invention relates to MAGE-3 specific primers and probes for use new diagnostic kits and methods. The invention further relates to immunotherapeutic treatment of specific populations of cancer patients, suffering from MAGE-3 expressing tumors.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: January 20, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Gabriele Annemarie Beer, Thierry Coche, Olivier Gruselle, Dennis Salonga, Craig Lawrence Stephens
  • Modified tuberculosis antigens
    Patent number: 8932600
    Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: January 13, 2015
    Assignees: GlaxoSmithKline Biologicals S.A., Glaxo Group Limited
    Inventors: Normand Blais, James Brown, Anne-Marie Gelinas, Pascal Mettens, Dennis Murphy
  • Conjugation process for PNAG and a carrier protein
    Patent number: 8933218
    Abstract: The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: January 13, 2015
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Tomas Maira-Litran
  • Vaccine
    Patent number: 8926985
    Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline Biologicals S A
    Inventors: Carine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
  • Method for Inducing a TRIF-Bias
    Publication number: 20150004180
    Abstract: Compositions comprising a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF-biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527.
    Type: Application
    Filed: December 23, 2013
    Publication date: January 1, 2015
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: WILLIAM S. BOWEN, Jay T. EVANS, MELINDA M. HUTTON, DAVID A. JOHNSON, LAURIE A. MINNS
  • CASB7439 constructs
    Patent number: 8916514
    Abstract: The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and for methods of utilizing the same.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: December 23, 2014
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Normand Blais, Martine Harvey, Anthony Pilorget, Clement Rioux, Remi Palmantier
  • Immunogenic composition
    Patent number: 8883163
    Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 11, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • LIPIDATED IMIDAZOQUINOLINE DERIVATIVES
    Publication number: 20140323731
    Abstract: The compounds of the subject invention are adjuvant molecules that comprise an imidazoquinoline molecule covalently linked to a phospho- or phosphonolipid group. The compounds of the invention have been shown to be inducers of interferon-a, IL-12 and other immunostimulatory cytokines and possess an improved activity profile in comparison to known cytokine inducers when used as adjuvants for vaccine antigens.
    Type: Application
    Filed: December 20, 2013
    Publication date: October 30, 2014
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: David A. JOHNSON
  • NOVEL METHOD
    Publication number: 20140315277
    Abstract: The present invention relates to a method for degrading host cell nucleic acids associated with a virus or a viral antigen thereof produced by cell culture, the method comprising at least two steps of nucleic acids degradation with a compound selected from i) an endonuclease and ii) a DNA alkylating agent.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 23, 2014
    Applicant: GlaxoSmithKline Biologicals s. a.
    Inventors: Bruno Rene ANDRE, Benoit Paul Suzanne Champluvier, Benedicte Van Der Hayden